The situation is likely to be different when HBV-TCR T-cell therapy is applied in patients with primary HBV-HCC without transplantation, given the absence of immunosuppressants and the shared recognition of HBV epitopes restricted by MHC molecules present on both tumour and non-transformed HBV infected hepatocytes. Here, HLA-C is linked to hepatocellular carcinoma.